Evaluation of intraindividual variability in hepatic CYP3A4 enzyme activity using endogenous markers in lung cancer patients treated with chemotherapeutic drugs and aprepitant
Not Applicable
Completed
- Conditions
- ung cancer patients treated with chemotherapeutic drugs and aprepitant
- Registration Number
- JPRN-UMIN000016952
- Lead Sponsor
- Keio University Faculty of Pharmacy
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients who required other chemotherapy 2)Patients who qre actively receiving inducer or inhibitor of CYP3A4 3)Patients who qre actively receiving androgen or estrogen preparation 4)Patients who qre actively receiving adrenal cortex hormone preparation without dexamethasone 5)Patients who qre actively receiving blood transfusion
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method